Oventus Medical Ltd (ASX: OVN) is pleased to advise that a peer-reviewed paper on Oventus’ clinical data has been published in the scientific journal, SLEEP® this week.
The paper demonstrates how Oventus’ O2Vent® mandibular advancement splint (MAS), used in combination with valves such as the ExVentTM* and O2Vent® OnePAPTM*, reduces the severity of Obstructive Sleep Apnoea (OSA) to therapeutic levels for a substantial proportion of incomplete/non-responder patients, compared to MAS therapy alone.
To read the publication abstract, click this link
Leave a Reply